Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Asthma–chronic obstructive pulmonary disease (COPD ... trials to evaluate specific drug interventions on important outcomes such as lung function, acute exacerbations, quality of life and ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

The 5th edition of Manipal Hospital Old Airport Road’s flagship workshop series, Handling Unexpected Emergencies (HUE), ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Jan. 27, 2025 — Researchers have uncovered a significant connection between elevated uric acid levels and life-threatening outcomes in children with severe ...